AndrewNDauberMDMMSc
Pediatric Endocrinology • Washington, DCPediatric Growth Disorder Endocrinology
Chief of Endocrinology, Children's National Medical Center
Dr. Dauber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Ave
Washington, DC 20010Phone+1 202-476-2121Fax+1 202-476-4095
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Endocrinology, 2008 - 2011- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2004 - 2008
Harvard Medical SchoolClass of 2004
Certifications & Licensure
MD State Medical License 2024 - 2026
VA State Medical License 2020 - 2026
DC State Medical License 2018 - 2025
MA State Medical License 2006 - 2020
OH State Medical License 2014 - 2019- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Endocrinology
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age Start of enrollment: 2011 Aug 01
- Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency Start of enrollment: 2018 Feb 01
- Vosoritide for Selected Genetic Causes of Short Stature Start of enrollment: 2020 Aug 04
Publications & Presentations
PubMed
- Treatment of Short Stature in Aggrecan-deficient Patients With Recombinant Human GH: 3-year Response.Gajanthan Muthuvel, Andrew Dauber, Eirene Alexandrou, Leah Tyzinski, Vivian Hwa
Journal of the Endocrine Society. 2024-10-29 - Phase 2 Trial of Vosoritide Use in Patients with Hypochondroplasia: A Pharmacokinetic/Pharmacodynamic Analysis.Despoina Galetaki, Anqing Zhang, Yulan Qi, Nadia Merchant, Roopa Kanakatti Shankar
Hormone Research in Paediatrics. 2024-10-18 - A Clinical Trial of High-Dose Growth Hormone in a Patient With a Dominant-Negative Growth Hormone Receptor Mutation.Nadia Merchant, Lisa Houchin, Kimberly Boucher, Andrew Dauber
The Journal of Clinical Endocrinology and Metabolism. 2024-10-15
Journal Articles
- Gain-of-Function DNMT3A Mutations Cause Microcephalic Dwarfism and Hypermethylation of Polycomb-Regulated RegionsAndrew Dauber, MD, Nature
- DLK1 Is a Novel Link Between Reproduction and MetabolismAndrew Dauber, MD, The Journal of Clinical Endocrinology and Metabolism
- Insights and Implications of Genome Wide Association Studies of HeightAndrew Dauber, MD, The Journal of Clinical Endocrinology and Metabolism
Press Mentions
Pharmacokinetic and Pharmacodynamic Analysis of Vosoritide in Phase 2 TrialNovember 18th, 2024
Promising Results After Precision Medicine Trial for Growth Hormone ResistanceMay 30th, 2024- Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesMay 3rd, 2023
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
